Dr. Christopher M Doran, MD Anesthesiology - Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 120 Avon Market Pl Ste 100, Avon, IN 46123 Phone: 317-396-1300 Fax: 317-396-1395 |
Dr. Andrew Gordon Cook, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 97 Dover St Ste 100, Avon, IN 46123 Phone: 317-706-7246 |
Neil J Martin, MD Anesthesiology - Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 10706 E Us Highway 36, Avon, IN 46123 Phone: 317-271-3600 Fax: 317-271-3604 |
Dr. Linda Lewis Lister, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 6319 E Us Highway 36, Suite 4, Avon, IN 46123 Phone: 317-345-6348 |
Ping Fu, MD., PH.D Anesthesiology - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1111 Ronald Reagan Pkwy, Avon, IN 46123 Phone: 317-577-4200 Fax: 317-577-9503 |
Dr. Christopher S Nelson, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 10706 E Us Highway 36, Suite # 7, Avon, IN 46123 Phone: 317-271-3600 Fax: 317-271-3604 |
Corey Joseph Mitscher, CAA Anesthesiology Medicare: Medicare Enrolled Practice Location: 1111 Ronald Reagan Pkwy, Avon, IN 46123 Phone: 317-217-3000 |
News Archive
As part of its ongoing commitment to the scientific community, Bayer Animal Health today marked their seventh year of support for the CVBD World Forum (CVBD7) in Berlin, Germany; and this year's meeting has again proven to be a landmark in the understanding of CVBDs.
For patients with both heart disease and diabetes who took part in a pooled series of rigorous clinical trials, the Resolute drug-eluting stent from Medtronic, Inc., provided remarkably safe and effective outcomes, according to the results of several studies presented today at EuroPCR, a major international meeting for cardiac and vascular specialists.
New research suggests that subcutaneous omalizumab is safe and effective an add-on treatment to corticosteroids for moderate to severe asthma in children and adults. Researchers from Uruguay, Argentina, and Chile performed a meta-analysis on eight trials where 1,883 patients received omalizumab and 1,546 received a placebo.
Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the hypertension treatment BenicarĀ® (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age. Benicar was originally approved in 2002 for the treatment of hypertension in adults.
Australian Medical Association (AMA) President, Dr Mukesh Haikerwal, said this week it is vitally important that the AMA takes a key coordinating role in planning the medical response to any disasters including terror attacks on Australian soil.
› Verified 6 days ago